Want to see FATE full AI Analyst Report?
FATE Stock Chart & Stats
$2.57
-$0.11(-4.37%)
At close: 4:00 PM EDT
$2.57
-$0.11(-4.37%)
Day’s Range― - ―
52-Week Range$0.93 - $3.23
Previous CloseN/A
Volume1.04M
Average Volume (3M)1.80M
Market Cap
$293.56M
Enterprise Value$246.98
Total Cash (Recent Filing)$153.77M
Total Debt (Recent Filing)$75.67M
Price to Earnings (P/E)―
Beta2.78
Next Earnings
Oct 29, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding119,820,510
10 Day Avg. Volume1,314,986
30 Day Avg. Volume1,798,369
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.70Price Target Upside160.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$5.65M
Bulls Say, Bears Say
Bulls Say
Off-the-shelf IPSC PlatformA scalable, allogeneic platform could reduce manufacturing complexity and support broader access than patient-specific therapies, creating a durable foundation for multiple oncology and immune-disorder programs.
Expanding Autoimmune PipelineProgress toward registrational development and expansion across lupus and other autoimmune indications increases pipeline optionality and could support future commercial scale if clinical efficacy and safety are demonstrated.
Moderate LeverageModerate leverage provides a better starting point than a heavily debt-funded balance sheet, potentially preserving financing flexibility while clinical programs advance, although ongoing losses remain a constraint.
Bears Say
Shrinking And Volatile RevenueA reduced and inconsistent revenue base limits internal funding capacity and indicates that commercial or partnership income has not yet become a dependable engine for supporting long-term operations.
Persistent Cash BurnSustained cash outflows require continued access to capital and raise the risk of financing-related dilution, particularly if clinical spending remains elevated before products generate meaningful revenue.
Deep Operating LossesNegative gross profit and large operating losses show that the business is still far from economic break-even, making future profitability dependent on successful clinical execution and eventual product commercialization.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $0.93 and its highest was $3.23 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is $293.56M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 54 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.254 by $0.004.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 119,820,510 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.254. Following the earnings report the stock price went down -7.353%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in FATE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.70 (160.70% Upside)
$6.70 (160.70% Upside)
Blogger Sentiment
Neutral
FATE Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 70.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $202.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
FATE Stock 12 Month Forecast
Average Price Target
$6.70
▲(160.70% Upside)
Technical Analysis
Ownership Overview
12.42% Insiders
12.29% Mutual Funds
17.64% Other Institutional Investors
52.08% Public Companies and
Individual Investors